 |
|
Reteplase in Acute Myocardial Infarction—Reply
|
|
| Since this article does not have an abstract, we have provided the first 119 words of the full text and any section headings. |
|
|
|
In Reply: In response to Dr Busti and colleagues, we reviewed the drugs received by patients before and after hospital admission (Table 1). Based on these data, we find no evidence of bias generated by concomitant drug therapy. However, we agree that the high initial dose of aspirin and the broad use of highly effective drugs, such as  -blockers, angiotensin-converting enzyme inhibitors, and statins, in our trial should be taken into account before extrapolating our findings to other settings.
Table appears in full text version.
|
|
|
|
Table. Drugs Received by Patients With Myocardial Infarction, Before and After Hospital Admission*
|
|
|
Financial Disclosure: Dr Schömig received research grants for the Department of Cardiology from Boston Scientific, Bristol-Myers Squibb, Cordis/Johnson & Johnson, Guidant, Hoffmann-La Roche, and Lilly.
Adnan Kastrati, MD
kastrati@dhm.mhn.de
Albert Schömig, MD
Deutsches Herzzentrum
Klinik an der Technischen Universität München
Munich, Germany
Letters Section Editor: Stephen J. Lurie, MD, PhD, Senior Editor.
JAMA. 2004;291:2430.
RELATED ARTICLES
Reteplase in Acute Myocardial Infarction
Anthony J. Busti, Kristen S. Marshall, and Justin S. Hooper
JAMA. 2004;291(20):2429-2430.
EXTRACT
| FULL TEXT
Early Administration of Reteplase Plus Abciximab vs Abciximab Alone in Patients With Acute Myocardial Infarction Referred for Percutaneous Coronary Intervention: A Randomized Controlled Trial
Adnan Kastrati, Julinda Mehilli, Klaus Schlotterbeck, Franz Dotzer, Josef Dirschinger, Claus Schmitt, Stephan G. Nekolla, Melchior Seyfarth, Stefan Martinoff, Christina Markwardt, Günther Clermont, Hans-Wilhelm Gerbig, Johannes Leiss, Markus Schwaiger, and Albert Schömig
JAMA. 2004;291(8):947-954.
ABSTRACT
| FULL TEXT
|
